WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 326632

CAS#: 153808-85-6 (free base)

Description: Cadrofloxacin, also known as Caderofloxacin and CS-940, is a novel fluoroquinolone antibacterial. The activities of CS-940 against gram-positive cocci and gram-negative rods, including methicillin-susceptible Staphylococcus aureus and penicillin-resistant Streptococcus pneumoniae, were comparable to those of tosufloxacin, with MICs at which 90% of the strains were inhibited (MIC90s) of 0.5 microg/ml or less. Against methicillin-resistant S. aureus, CS-940 was as active as tosufloxacin, with a MIC90 of 16 microg/ml. The efficacy of CS-940 against murine respiratory infections due to S. pneumoniae or Haemophilus influenzae was better than those of tosufloxacin and sparfloxacin. The efficacy of oral doses of CS-940 reflected not only potent in vitro activity but also a high transmigration ratio from the bloodstream to lung tissues.

Price and Availability




Cadrofloxacin is not in stock, may be available through custom synthesis. For cost-effective reason, minimum 1 gram order is requested. The product will be characterized by NMR, HPLC and MS analysis. Purity (HPLC) is usually >98%. CoA, QC data, MSDS will be provided when product is successfully made. The estimated lead time is 2-3 months. Please send email to to inquire quote.

Chemical Structure


Theoretical Analysis

MedKoo Cat#: 326632
Name: Cadrofloxacin
CAS#: 153808-85-6 (free base)
Chemical Formula: C19H20F3N3O4
Exact Mass: 411.1406
Molecular Weight: 411.3812
Elemental Analysis: C, 55.47; H, 4.90; F, 13.85; N, 10.21; O, 15.56

Synonym: CS-940; CS 940; CS940; Cadrofloxacin; Caderofloxacin; Cadrofloxacin hydrochloride; Cadrofloxacin HCl.

IUPAC/Chemical Name: (S)-1-cyclopropyl-8-(difluoromethoxy)-6-fluoro-7-(3-methylpiperazin-1-yl)-4-oxo-1,4-dihydroquinoline-3-carboxylic acid


InChi Code: InChI=1S/C19H20F3N3O4/c1-9-7-24(5-4-23-9)15-13(20)6-11-14(17(15)29-19(21)22)25(10-2-3-10)8-12(16(11)26)18(27)28/h6,8-10,19,23H,2-5,7H2,1H3,(H,27,28)/t9-/m0/s1

SMILES Code: O=C(C1=CN(C2CC2)C3=C(C=C(F)C(N4C[C@H](C)NCC4)=C3OC(F)F)C1=O)O

Technical Data

Solid powder

>98% (or refer to the Certificate of Analysis)

Shipping Condition:
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition:
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Soluble in DMSO, not in water

Shelf Life:
>2 years if stored properly

Drug Formulation:
This drug may be formulated in DMSO

Stock Solution Storage:
0 - 4 C for short term (days to weeks), or -20 C for long term (months).

Harmonized System Code:

Additional Information

Related CAS#
153808-85-6 (free base); 128427-55-4 (HCl).


1: Ma RL, Zhou HH, Liu R, Wang EH, Sheng LS. [Analysis of impurity in caderofloxacin]. Yao Xue Xue Bao. 2003 Dec;38(12):950-2. Chinese. PubMed PMID: 15040093.

2: Kawahara S, Tada A, Nagare H. [Clinical evaluation of new quinolones as antituberculosis drugs]. Kekkaku. 1999 Jan;74(1):71-5. Review. Japanese. PubMed PMID: 10067058.

3: Namba K. [View of development of fluoroquinolones]. Kekkaku. 1999 Jan;74(1):47-52. Review. Japanese. PubMed PMID: 10067055.

4: Kawahara S. [Chemotherapeutic agents under study]. Nihon Rinsho. 1998 Dec;56(12):3096-9. Review. Japanese. PubMed PMID: 9883617.

5: Miyazaki S, Domon H, Tateda K, Ohno A, Ishii Y, Matsumoto T, Furuya N, Yamaguchi K. In vitro and in vivo antibacterial activities of CS-940, a new fluoroquinolone, against isolates from patients with respiratory infections. Antimicrob Agents Chemother. 1997 Nov;41(11):2582-5. PubMed PMID: 9371375; PubMed Central PMCID: PMC164170.

6: Schmitz FJ, Jones ME. Antibiotics for treatment of infections caused by MRSA and elimination of MRSA carriage. What are the choices? Int J Antimicrob Agents. 1997 Jun;9(1):1-19. PubMed PMID: 18611815.

7: Mizutani S. [Chemotherapy of pulmonary Mycobacterium kansasii infection]. Kekkaku. 1996 Sep;71(9):527-31. Japanese. PubMed PMID: 8914388.

8: Takenouchi T, Tabata F, Iwata Y, Hanzawa H, Sugawara M, Ohya S. Hydrophilicity of quinolones is not an exclusive factor for decreased activity in efflux-mediated resistant mutants of Staphylococcus aureus. Antimicrob Agents Chemother. 1996 Aug;40(8):1835-42. PubMed PMID: 8843290; PubMed Central PMCID: PMC163426.

9: Yamane N, Chilima BZ, Tosaka M, Okazawa Y, Tanno K. [Determination of antimycobacterial activities of fluoroquinolones against clinical isolates of Mycobacterium tuberculosis: comparative determination with egg-based Ogawa and agar-based Middlebrook 7H10 media]. Kekkaku. 1996 Aug;71(8):453-8. Japanese. PubMed PMID: 8831190.

10: Masuda N, Takahashi Y, Otsuki M, Ibuki E, Miyoshi H, Nishino T. In vitro and in vivo antibacterial activities of CS-940, a new 6-fluoro-8-difluoromethoxy quinolone. Antimicrob Agents Chemother. 1996 May;40(5):1201-7. PubMed PMID: 8723467; PubMed Central PMCID: PMC163292.

11: Biedenbach DJ, Sutton LD, Jones RN. Antimicrobial activity of CS-940, a new trifluorinated quinolone. Antimicrob Agents Chemother. 1995 Oct;39(10):2325-30. PubMed PMID: 8619590; PubMed Central PMCID: PMC162937.